Eli Lilly Launches Mounjaro Pen in India as Obesity Drug Race Heats Up

Eli Lilly launches Mounjaro pen in India as obesity drug race heats up

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to capture India’s growing anti-obesity market as Novo Nordisk pushes Wegovy.

Eli Lilly’s Mounjaro in a pen-like device, increases options in the diabetes and weightloss segment

Eli Lilly launches Mounjaro KwikPen in India for Type 2 diabetes and weightloss, offering personalized treatment plans.

Eli Lilly Launches Mounjaro Kwikpen in India, Intensifying Weight-Loss Drug Market Rivalry

Eli Lilly has introduced its easy-to-use Mounjaro Kwikpen in India, priced at ₹14,000 (about $160) for the starting 2.5 mg dose, aiming to strengthen its foothold in the booming weight-loss drug segment. The launch follows regulatory approval in June, just two days after rival Novo Nordisk rolled out its Wegovy pen device in multiple dose strengths. Mounjaro will be available in six strengths ranging from 2.5 mg to 15 mg, with monthly prices ris…

Eli Lilly Launches Mounjaro KwikPen in India with Six Dosage Options for Type 2 Diabetes Treatment

Pharmaceutical company Eli Lilly has introduced its Mou […] The post Eli Lilly Launches Mounjaro KwikPen in India with Six Dosage Options for Type 2 Diabetes Treatment first appeared on GeneOnline News. The post Eli Lilly Launches Mounjaro KwikPen in India with Six Dosage Options for Type 2 Diabetes Treatment appeared first on GeneOnline News.

Lilly’s Mounjaro KwikPen (tirzepatide) launched in India - Express Healthcare

Eli Lilly and Company announced that Mounjaro KwikPen (tirzepatide) is now available across India in all doses. Approved by the Central Drugs Standard Control Organisation (CDSCO), Mounjaro KwikPen, a prescription-based, once-weekly treatment, offers a convenient way for patients to administer their medication. Mounjaro is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicate…